Maravai LifeSciences Holdings Inc [MRVI] stock prices are up 10.60% to $2.40 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The MRVI shares have gain 16.50% over the last week, with a monthly amount glided 35.59%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] stock has seen the most recent analyst activity on February 26, 2025, when Robert W. Baird downgraded its rating to a Neutral and also revised its price target to $3 from $9. On December 05, 2024, downgrade downgraded it’s rating to Sell but maintained its price target of $4.25 on the stock. Wolfe Research started tracking the stock assigning a Peer Perform rating. William Blair downgraded its rating to a Mkt Perform. Wells Fargo started tracking with a Overweight rating for this stock on August 28, 2024, and assigned it a price target of $10. In a note dated August 13, 2024, Morgan Stanley downgraded an Equal-Weight rating on this stock and revised its target price from $11 to $10.
The stock price of Maravai LifeSciences Holdings Inc [MRVI] has been fluctuating between $1.66 and $11.50 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] shares were valued at $2.40 at the most recent close of the market. An investor can expect a potential return of 108.33% based on the average MRVI price forecast.
Analyzing the MRVI fundamentals
The Maravai LifeSciences Holdings Inc [NASDAQ:MRVI] reported sales of 241.86M for trailing twelve months, representing a drop of -27.00%. Gross Profit Margin for this corporation currently stands at 0.37% with Operating Profit Margin at -1.1%, Pretax Profit Margin comes in at -1.21%, and Net Profit Margin reading is -0.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.46 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Maravai LifeSciences Holdings Inc [NASDAQ:MRVI]’s Current Ratio is 5.96. On the other hand, the Quick Ratio is 5.17, and the Cash Ratio is 4.51. Considering the valuation of this stock, the price to sales ratio is 2.53, the price to book ratio is 1.15.
Transactions by insiders
Recent insider trading involved ORESHACK KURT, General Counsel, that happened on Jan 31 ’25 when 25000.0 shares were sold. Officer, ORESHACK KURT completed a deal on Jan 31 ’25 to buy 25000.0 shares. Meanwhile, Director DeFord John A bought 17500.0 shares on Nov 12 ’24.
